498 related articles for article (PubMed ID: 1904120)
1. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
3. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
4. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group.
Rintala E; Jauhiainen K; Kaasinen E; Nurmi M; Alfthan O
J Urol; 1996 Jul; 156(1):56-9; discussion 59-60. PubMed ID: 8648837
[TBL] [Abstract][Full Text] [Related]
5. [Long-term results and risk factors of tumor recurrence in patients with superficial bladder cancer who were treated by intravesical bacillus Calmette-Guerin (BCG) instillation].
Tachibana M; Nakamura S; Jitsukawa S; Deguchi N; Baba S; Hata M; Tazaki H
Nihon Hinyokika Gakkai Zasshi; 1993 Apr; 84(4):656-61. PubMed ID: 8492508
[TBL] [Abstract][Full Text] [Related]
6. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K
J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG
Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718
[TBL] [Abstract][Full Text] [Related]
8. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
Rintala E; Jauhiainen K; Alfthan O; Hansson E; Juusela H; Kanerva K; Korhonen H; Permi J; Sotarauta M; Vaalasti T
Eur Urol; 1991; 20(1):19-25. PubMed ID: 1743226
[TBL] [Abstract][Full Text] [Related]
9. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer.
Okamura T; Tozawa K; Yamada Y; Sakagami H; Ueda K; Kohri K
J Urol; 1996 Sep; 156(3):967-71. PubMed ID: 8709375
[TBL] [Abstract][Full Text] [Related]
11. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
12. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
13. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
Yamada Y; Washida H; Tozawa K; Honma H; Kang K
Hinyokika Kiyo; 1994 Jul; 40(7):575-9. PubMed ID: 8085517
[TBL] [Abstract][Full Text] [Related]
14. Single monthly bacillus Calmette-Guérin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer.
Okamura T; Akita H; Ando R; Ikegami Y; Naiki T; Kawai N; Tozawa K; Kohri K
Int J Clin Oncol; 2012 Oct; 17(5):477-81. PubMed ID: 21947596
[TBL] [Abstract][Full Text] [Related]
15. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
Krege S; Giani G; Meyer R; Otto T; Rübben H
J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374
[TBL] [Abstract][Full Text] [Related]
16. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
17. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
[TBL] [Abstract][Full Text] [Related]
18. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.
Pfister C; Kerkeni W; Rigaud J; Le Gal S; Saint F; Colombel M; Guy L; Wallerand H; Irani J; Soulie M;
Int J Urol; 2015 Jan; 22(1):53-60. PubMed ID: 25256813
[TBL] [Abstract][Full Text] [Related]
20. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Lundholm C; Norlén BJ; Ekman P; Jahnson S; Lagerkvist M; Lindeborg T; Olsson JL; Tveter K; Wijkstrom H; Westberg R; Malmström PU
J Urol; 1996 Aug; 156(2 Pt 1):372-6. PubMed ID: 8683682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
